Evidence map›Paper›PMID 22891074›Full record

ArticleFrontiers in genetics2012

Germline copy number variation and ovarian cancer survival.

Brooke L Fridley, Prabhakar Chalise, Ya-Yu Tsai, Zhifu Sun, Robert A Vierkant, Melissa C Larson, Julie M Cunningham, Edwin S Iversen, David Fenstermacher, Jill Barnholtz-Sloan and 7 more

Abstract read
In one paragraph

Article in Frontiers in genetics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2017
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Genome-wide Analysis of Common Copy Number Variation and Epithelial Ovarian Cancer Risk.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019
    Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Brooke L FridleyDepartment of Health Sciences Research, Mayo Clinic Rochester, MN, USA.
Prabhakar Chalise
Ya-Yu Tsai
Zhifu Sun
Robert A Vierkant
Melissa C Larson
Julie M Cunningham
Edwin S Iversen
David Fenstermacher
Jill Barnholtz-Sloan
Yan Asmann
Harvey A Risch
Joellen M Schildkraut
Catherine M Phelan
Rebecca Sutphen
Thomas A Sellers
Ellen L Goode

Funding

Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0M
Ovarian cancer GWAS discovery, expansion and replication (N2 - Project #1)U19CA148112 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SELLERS, THOMAS A · 2010 to 2014
$10.2M
Haplotype-Based Genome Screen for Ovarian Cancer LociR01CA114343 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SELLERS, THOMAS A · 2007 to 2011
$7.5M
The Mitochondrial Genome and Ovarian Cancer RiskR01CA149429 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI PHELAN, CATHERINE · 2010 to 2015
$3.1M
Population-Based Analysis of Ovarian Cancer BiomarkersR01CA106414 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI SUTPHEN, REBECCA · 2005 to 2009
$3.0M
Genetic Variation in the NF-kappaB Pathway and Ovarian Cancer EtiologyR01CA122443 · NCI · MAYO CLINIC ROCHESTER · PI GOODE, ELLEN L. · 2007 to 2012
$2.7M
Integrative genomic models for analysis of pharmacogenomic studiesR21CA140879 · NCI · MAYO CLINIC ROCHESTER · PI FRIDLEY, BROOKE L · 2009 to 2010
$299k
Bayesian hierarchical nonlinear models for pharmacogenomic cytotoxicity studiesR21GM086689 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI FRIDLEY, BROOKE L · 2011 to 2012
$232k
NCI NIH HHS P50 CA136393NCI NIH HHS R01 CA106414NCI NIH HHS R01 CA114343NCI NIH HHS R01 CA122443NCI NIH HHS R01 CA149429NCI NIH HHS R21 CA140879NCI NIH HHS U19 CA148112NIGMS NIH HHS R21 GM086689
6 · The paper itself

Abstract

Copy number variants (CNVs) have been implicated in many complex diseases. We examined whether inherited CNVs were associated with overall survival among women with invasive epithelial ovarian cancer. Germline DNA from 1,056 cases (494 deceased, average of 3.7 years follow-up) was interrogated with the Illumina 610 quad genome-wide array containing, after quality control exclusions, 581,903 single nucleotide polymorphisms (SNPs) and 17,917 CNV probes. Comprehensive analysis capitalized upon the strengths of three complementary approaches to CNV classification. First, to identify small CNVs, single markers were evaluated and, where associated with survival, consecutive markers were combined. Two chromosomal regions were associated with survival using this approach (14q31.3 rs2274736 p = 1.59 × 10(-6), p = 0.001; 22q13.31 rs2285164 p = 4.01 × 10(-5), p = 0.009), but were not significant after multiple testing correction. Second, to identify large CNVs, genome-wide segmentation was conducted to characterize chromosomal gains and losses, and association with survival was evaluated by segment. Four regions were associated with survival (1q21.3 loss p = 0.005, 5p14.1 loss p = 0.004, 9p23 loss p = 0.002, and 15q22.31 gain p = 0.002); however, again, after correcting for multiple testing, no regions were statistically significant, and none were in common with the single marker approach. Finally, to evaluate associations with general amounts of copy number changes across the genome, we estimated CNV burden based on genome-wide numbers of gains and losses; no associations with survival were observed (p > 0.40). Although CNVs that were not well-covered by the Illumina 610 quad array merit investigation, these data suggest no association between inherited CNVs and survival after ovarian cancer.

Indexed as

association testingcopy number variationgenotyping arrayovarian canceroverall survival

Identifiers

PMID22891074
PMCPMC3413872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.